Medical Sciences


Novel Cationic 17-Estradiol-Substituted-Estradiol Derivatives with Anti-cancer Activity


Medical Sciences

Focus Area:

Cancer Treatment


EP2111409, IN263345, JP5276020, US8012952

Social Benefits:

These Estrogen-structure based molecules have the ability to kill cancer cells of all stages of breast cancer. Other existing estrogen-based or estrogenic anticancer molecule acts against estrogen receptor (ER)-expressing breast cancer cells only. So, this molecule is 'fit-for-all' breast cancerphenotypes, These molecules have anticancer effect against other ER-expressing cancer cells, such as ovarian carcinoma, melanoma, pancreatic cancer, It is orally administrable (whereas estrogenic, anti-breast cancer drug FaslodexTM is intramuscularly injectable only). Hence, it holds the promise to become the first oral breast cancerdrug developed from India

Developing Agency:

CSIR-Indian Institute of Chemical Technology (IICT), Telangana

Technology Readiness Index:

Lab Validation

Website Link :
Source (more info) :

Brief Description

Description :

Tested preclinically in triple negative breast tumor animal model (the most aggressive breast cancer model). The molecule is co-formulated in liposomes and developed further in association with Mayo Clinic, USA for treating multiple other aggressive cancers such as melanoma, pancreatic cancer.

Related Technologies